Trial Profile
A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Aug 2012
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jul 2011 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2011 Results presented at the 14th World Conference on Lung Cancer.
- 07 Jun 2011 Actual patient number (n=135) reported at the American Society of Clinical Oncology Annual Meeting 2011. Additional identifier also reported (KCSG-LU08-01).